About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth driven by SYFOVRE, while navigating market challenges ...

THE last thing Lau remembered were the cries of his grade three pupils, shaking him and tapping his legs before he totally ...

Thank you for standing by, and welcome to the Apellis Pharmaceuticals fourth quarter and full year 2024 earnings conference call. (Operator Instructions) After the speaker's presentation, there will ...

Sickle Cell Disease is a complex and debilitating genetic blood disorder that primarily affects people of African, ...